Vault-13

Aquilo Capital Management, LLC

SAN FRANCISCO, CA · CIK 1591986 · 13F filing filed 2025-02-14

No investment adviser registration (Form ADV) found for this filer. It may be a parent company whose subsidiaries are the registered advisers, a bank or insurer, or a manager based outside the US.

$58.4m reported value -34.3% vs Q3 2024
13positions
93.6%in top 10
1 new 6 added 5 reduced 1 sold out vs Q3 2024

Options: 2 call positions ($7.9m notional), 0 put positions (— notional) – listed below, not included above.

Holdings, Q4 2024

The small lines show how much was held over the last 4 quarters (adjusted for stock splits).

#SecurityTickerShares Value% of portfolioChangeShares change
1 ARROWHEAD PHARMACEUTICALS IN COM ARWR ARWR 707,589 $13.3m22.78% 22.78% ReducedShares held: Q1 2024 908.5k, Q2 2024 908.5k, Q3 2024 795.8k, Q4 2024 707.6k -88.2k -88,224 -11.1%
2 BLUEPRINT MEDICINES CORP COM BPMC BPMC 129,600 $11.3m19.36% 19.36% AddedShares held: Q1 2024 182.2k, Q2 2024 114.6k, Q3 2024 124.6k, Q4 2024 129.6k +5.0k +5,000 4.0%
3 KYMERA THERAPEUTICS INC COM KYMR KYMR 183,521 $7.4m12.64% 12.64% ReducedShares held: Q1 2024 388.7k, Q2 2024 328.7k, Q3 2024 208.7k, Q4 2024 183.5k -25.2k -25,222 -12.1%
4 ARVINAS INC COM ARVN ARVN 328,766 $6.3m10.79% 10.79% ReducedShares held: Q1 2024 405.8k, Q2 2024 428.8k, Q3 2024 388.8k, Q4 2024 328.8k -60.0k -60,000 -15.4%
5 BICYCLE THERAPEUTICS PLC SPONSORED ADS BCYC BCYC 221,911 $3.1m5.32% 5.32% AddedShares held: Q1 2024 0, Q2 2024 156.7k, Q3 2024 181.9k, Q4 2024 221.9k +40.0k +40,000 22.0%
6 PROTAGONIST THERAPEUTICS INC COM PTGX PTGX 76,592 $3.0m5.06% 5.06% NewShares held: Q1 2024 0, Q2 2024 0, Q3 2024 0, Q4 2024 76.6k
7 REGENXBIO INC COM RGNX RGNX 346,302 $2.7m4.58% 4.58% ReducedShares held: Q1 2024 906.2k, Q2 2024 906.2k, Q3 2024 930.7k, Q4 2024 346.3k -584.4k -584,406 -62.8%
8 IMMATICS N.V SHS IMTX IMTX 373,902 $2.7m4.55% 4.55% AddedShares held: Q1 2024 0, Q2 2024 200.0k, Q3 2024 333.5k, Q4 2024 373.9k +40.4k +40,400 12.1%
9 SILENCE THERAPEUTICS PLC ADS SLN SLN 367,214 $2.5m4.33% 4.33% AddedShares held: Q1 2024 574.2k, Q2 2024 500.2k, Q3 2024 317.2k, Q4 2024 367.2k +50.0k +50,000 15.8%
10 ADICET BIO INC COM COM 2,531,194 $2.4m4.17% 4.17% UnchangedShares held: Q1 2024 0, Q2 2024 2.5m, Q3 2024 2.5m, Q4 2024 2.5m
11 PRECISION BIOSCIENCES INC COM NEW DTIL DTIL 536,376 $2.0m3.50% 3.50% AddedShares held: Q1 2024 385.4k, Q2 2024 381.8k, Q3 2024 381.8k, Q4 2024 536.4k +154.6k +154,573 40.5%
12 REPARE THERAPEUTICS INC COM RPTX RPTX 1,293,715 $1.7m2.90% 2.90% AddedShares held: Q1 2024 633.3k, Q2 2024 956.9k, Q3 2024 989.4k, Q4 2024 1.3m +304.4k +304,351 30.8%
13 SUTRO BIOPHARMA INC COM COM 498 $9160.00% 0.00% ReducedShares held: Q1 2024 1.2m, Q2 2024 762.5k, Q3 2024 762.5k, Q4 2024 498 -762.0k -762,000 -99.9%

Sold out since Q3 2024

SecurityTickerShares held beforeValue then
MERUS N V MRUS MRUS 117,855 $5.9m117.9k shares

Options (notional value)

UnderlyingTickerTypeShares controlled NotionalChange
AMGEN INC AMGN · Call AMGNCall 25,000 $6.5m25.0k shares New
ARROWHEAD PHARMACEUTICALS IN ARWR · Call ARWRCall 75,000 $1.4m75.0k shares New